Clinical outcomes with first-line chemotherapy versus endocrine therapy for adjuvant endocrine therapy-resistant metastatic breast cancer

• DOI: 10.21037/22036
• Publication Date: 2018-06-16
• Authors: Bin Shao; Yanlian Yang; Jinrong Qu; Huiping Li; Guohong Song; Lijun Di; Hanfang Jiang; Ying Yan; Huan Wang; Xiaoran Liu; Jing Wang; Weiyao Kong
• Keywords: Progression-free survival; Adjuvant Therapy

Background: Endocrine therapy resistance (ETR) is a great obstacle in the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer. Patients with ETR have significantly decreased clinical benefit from endocrine (ET). Therefore, it quite important to find clinicopathological factors that affect outcome patients practice. Methods: We screened 405 consecutive ER+/HER2− metastatic cancer (MBC) who were treated 2013–2015 our hospital. (defined as relapse during adjuvant ET or within 12 months after completing ET) selected explore affecting objective response rate (ORR) and progression-free survival (PFS). Results: included 135 study. Chemotherapy (CT) was administered 96 39 first-line treatment. liver visceral metastasis received CT more frequently than (P=0.001, 0.001). There no significant difference median PFS between two groups (ET: 11.8 months, CT: 12.0 P=0.931, HR =1.029). However, sites had shorter less equal (7.5 vs. 14.5 P=0.031, =1.714). When on further stratified, those maintenance longer (14.3 months) compared did not (P=0.003). Conclusions: both appropriate treatments for ETR. Maintenance good choice patients.